drugset / Trial / NCT07153055
Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
This open-label, Phase I/II trial is studying the safety and effectiveness of an experimental drug combination, lurbinectedin with osimertinib, against a rare type of cancer known as transformed small cell lung cancer (SCLC).
Timeline
- Start
- 2026-08
- Primary completion
- 2029-04
- Completion
- 2029-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lurbinectedin | Other / unclassified | 2.6 mg/m2 | — |
| Subject | Lurbinectedin | Other / unclassified | 3.2 mg/m2 | — |
| Subject | Osimertinib | Small molecule | 40 mg | Oral |
| Subject | Osimertinib | Small molecule | 80 mg | Oral |